RBPWorld - a comprehensive database of RNA Binding Proteins

Drugs target to EEF2

Drug name	Drug type	Disease/phenotype	Mechanism of action(MoA)	Phase	Status	Source
DENILEUKIN DIFTITOX	Protein	peritoneum cancer	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	neoplasm	Elongation factor 2 inhibitor	4.0	-	ATC
MOXETUMOMAB PASUDOTOX	Antibody	lymphoma	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	leukemia	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	lymphoma	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
TAGRAXOFUSP	Protein	acute myeloid leukemia	Elongation factor 2 inhibitor	4.0	-	FDA
MOXETUMOMAB PASUDOTOX	Antibody	non-Hodgkins lymphoma	Elongation factor 2 inhibitor	1.0	Unknown status	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	ovarian cancer	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
LMB-100	Unknown	cancer	Elongation factor 2 disrupting agent	1.0	Terminated	ClinicalTrials
LMB-100	Unknown	pancreatic neoplasm	Elongation factor 2 disrupting agent	1.0	Completed	ClinicalTrials
TAGRAXOFUSP	Protein	blastic plasmacytoid dendritic cell neoplasm	Elongation factor 2 inhibitor	2.0	Recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	pancreatic carcinoma	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	ovarian cancer	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	chronic lymphocytic leukemia	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	melanoma	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
LMB-100	Unknown	mesothelioma	Elongation factor 2 disrupting agent	1.0	Recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	unspecified peripheral T-cell lymphoma	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	Cutaneous T-cell lymphoma	Elongation factor 2 inhibitor	4.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	ovarian serous cystadenocarcinoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	ovarian mucinous cystadenocarcinoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	cutaneous melanoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
RESIMMUNE	Unknown	mycosis fungoides	Elongation factor 2 inhibitor	2.0	Unknown status	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	T-cell acute lymphoblastic leukemia	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	toxicity	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
LMB-100	Unknown	mesothelioma	Elongation factor 2 disrupting agent	2.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	Fallopian Tube Carcinoma	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	Fallopian Tube Carcinoma	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	neoplasm	Elongation factor 2 inhibitor	4.0	-	ATC
MOXETUMOMAB PASUDOTOX	Antibody	hairy cell leukemia	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	endometrioid carcinoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	childhood acute lymphoblastic leukemia	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	unspecified peripheral T-cell lymphoma	Elongation factor 2 inhibitor	3.0	Withdrawn	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	leukemia	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
RESIMMUNE	Unknown	mycosis fungoides	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	peritoneum cancer	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
TAGRAXOFUSP	Protein	chronic myelomonocytic leukemia	Elongation factor 2 inhibitor	1.0	Recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	lymphoma	Elongation factor 2 inhibitor	3.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	kidney cancer	Elongation factor 2 inhibitor	0.5	Completed	ClinicalTrials
TAGRAXOFUSP	Protein	acute myeloid leukemia	Elongation factor 2 inhibitor	2.0	Recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	ovarian cancer	Elongation factor 2 inhibitor	1.0	Recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	melanoma	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
RESIMMUNE	Unknown	Sezary's disease	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	multiple myeloma	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	male breast carcinoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	graft versus host disease	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	chronic lymphocytic leukemia	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	unspecified peripheral T-cell lymphoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
RESIMMUNE	Unknown	melanoma	Elongation factor 2 inhibitor	1.0	Unknown status	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	mycosis fungoides	Elongation factor 2 inhibitor	4.0	Completed	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	hairy cell leukemia	Elongation factor 2 inhibitor	1.0	Unknown status	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	unspecified peripheral T-cell lymphoma	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
LMB-100	Unknown	lung adenocarcinoma	Elongation factor 2 disrupting agent	2.0	Active, not recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	Sezary's disease	Elongation factor 2 inhibitor	4.0	Completed	ClinicalTrials
RESIMMUNE	Unknown	T-cell leukemia	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	chronic lymphocytic leukemia	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
LMB-100	Unknown	mesothelioma	Elongation factor 2 disrupting agent	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	peritoneum cancer	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	leukemia	Elongation factor 2 inhibitor	1.0	Withdrawn	ClinicalTrials
LMB-100	Unknown	mesothelioma	Elongation factor 2 disrupting agent	1.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	ovarian clear cell cystadenocarcinoma	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	melanoma	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	fallopian tube cancer	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials
TAGRAXOFUSP	Protein	myelodysplastic syndrome	Elongation factor 2 inhibitor	1.0	Recruiting	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	leukemia	Elongation factor 2 inhibitor	1.0	Unknown status	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	lymphoma	Elongation factor 2 inhibitor	2.0	Unknown status	ClinicalTrials
TAGRAXOFUSP	Protein	blastic plasmacytoid dendritic cell neoplasm	Elongation factor 2 inhibitor	1.0	Recruiting	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	hairy cell leukemia	Elongation factor 2 inhibitor	4.0	-	FDA
TAGRAXOFUSP	Protein	blastic plasmacytoid dendritic cell neoplasm	Elongation factor 2 inhibitor	2.0	Active, not recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	lymphoma	Elongation factor 2 inhibitor	2.0	Withdrawn	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	acute myeloid leukemia	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
TAGRAXOFUSP	Protein	acute myeloid leukemia	Elongation factor 2 inhibitor	2.0	Not yet recruiting	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	hairy cell leukemia	Elongation factor 2 inhibitor	3.0	Completed	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	hairy cell leukemia	Elongation factor 2 inhibitor	1.0	Recruiting	ClinicalTrials
TAGRAXOFUSP	Protein	neoplasm	Elongation factor 2 inhibitor	4.0	-	ATC
DENILEUKIN DIFTITOX	Protein	non-Hodgkins lymphoma	Elongation factor 2 inhibitor	2.0	Completed	ClinicalTrials
TAGRAXOFUSP	Protein	acute myeloid leukemia	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	leukemia	Elongation factor 2 inhibitor	2.0	Unknown status	ClinicalTrials
RESIMMUNE	Unknown	melanoma	Elongation factor 2 inhibitor	1.0	Terminated	ClinicalTrials
TAGRAXOFUSP	Protein	acute myeloid leukemia	Elongation factor 2 inhibitor	1.0	Recruiting	ClinicalTrials
DENILEUKIN DIFTITOX	Protein	Cutaneous T-cell lymphoma	Elongation factor 2 inhibitor	4.0	-	DailyMed
MOXETUMOMAB PASUDOTOX	Antibody	acute lymphoblastic leukemia	Elongation factor 2 inhibitor	2.0	Terminated	ClinicalTrials
MOXETUMOMAB PASUDOTOX	Antibody	acute lymphoblastic leukemia	Elongation factor 2 inhibitor	1.0	Completed	ClinicalTrials

Welcome to

RBP World!

Drugs target to EEF2

Targets details